NASDAQ:GRFS

Grifols (GRFS) Stock Price, News & Analysis

$6.35
-0.13 (-2.01%)
(As of 03:46 PM ET)
Today's Range
$6.29
$6.44
50-Day Range
$5.47
$9.34
52-Week Range
$5.30
$12.15
Volume
740,534 shs
Average Volume
2.92 million shs
Market Capitalization
$4.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Grifols MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
66.1% Upside
$10.50 Price Target
Short Interest
Healthy
2.32% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.38mentions of Grifols in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
60.00%
From $0.85 to $1.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.57 out of 5 stars

GRFS stock logo

About Grifols Stock (NASDAQ:GRFS)

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

GRFS Stock Price History

GRFS Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
GRFS Nov 2024 3.000 put
GRFS Apr 2024 11.000 call
See More Headlines
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/04/2021
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRFS
Employees
26,314
Year Founded
1909

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$10.50
Low Stock Price Target
$10.50
Potential Upside/Downside
+62.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$131.34 million
Pretax Margin
3.40%

Debt

Sales & Book Value

Annual Sales
$6.59 billion
Cash Flow
$0.81 per share
Book Value
$12.61 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.46 billion
Optionable
Optionable
Beta
0.56

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Thomas H. Glanzmann (Age 66)
    CEO & Executive Chairman
    Comp: $162.48k
  • Mr. Alfredo Arroyo Guerra (Age 66)
    CFO & VP
  • Mrs. Eva Bastida Tubau
    Corporate Vice President and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña (Age 60)
    VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
  • Mr. David Ian Bell (Age 70)
    Chief Corporate Development, Legal & Data Protection Officer
  • Ms. Maria Teresa-Rioné Llano (Age 59)
    Chief Communications Officer
  • Ms. Montserrat Gaja Llamas (Age 59)
    Chief Human Resources Officer
  • Mr. Vicente Blanquer Torre (Age 63)
    Chief Quality Officer
  • Mr. Alberto Grifols Roura (Age 65)
    President of the Bio Supplies Division
  • Mr. Sergio Roura Adell (Age 56)
    President of Commercial Tech Support

GRFS Stock Analysis - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GRFS shares.
View GRFS analyst ratings
or view top-rated stocks.

What is Grifols' stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for Grifols' shares. Their GRFS share price targets range from $10.50 to $10.50. On average, they expect the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 66.1% from the stock's current price.
View analysts price targets for GRFS
or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2024?

Grifols' stock was trading at $11.56 at the start of the year. Since then, GRFS stock has decreased by 45.3% and is now trading at $6.32.
View the best growth stocks for 2024 here
.

Are investors shorting Grifols?

Grifols saw a decline in short interest in March. As of March 31st, there was short interest totaling 5,970,000 shares, a decline of 27.1% from the March 15th total of 8,190,000 shares. Based on an average daily trading volume, of 3,250,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.3% of the company's shares are sold short.
View Grifols' Short Interest
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) posted its earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter. Grifols had a trailing twelve-month return on equity of 1.73% and a net margin of 1.84%.

Is Grifols a good dividend stock?

Grifols (NASDAQ:GRFS) pays an annual dividend of $0.36 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for GRFS.

What ETFs hold Grifols' stock?

ETFs with the largest weight of Grifols (NASDAQ:GRFS) stock in their portfolio include Brandes International ETF (BINV).Brandes U.S. Small-Mid Cap Value ETF (BSMC).

When did Grifols' stock split?

Grifols shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Grifols issued on next quarter's earnings?

Grifols issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.6 billion-, compared to the consensus revenue estimate of $7.7 billion.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?
Who are Grifols' major shareholders?

Grifols' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.00%), First Trust Direct Indexing L.P. (0.00%) and Cohen Investment Advisors LLC (0.00%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
This page (NASDAQ:GRFS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners